<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New treatment strategies for subjects with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are being developed </plain></SENT>
<SENT sid="1" pm="."><plain>Pilot studies utilising insulin itself have been reported to prevent Type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> in subjects likely, by immunogenetic and physiologic criteria, to develop clinically overt disease, while the results of nicoti-namide trials in these subjects remain preliminary </plain></SENT>
<SENT sid="2" pm="."><plain>Immunotherapy with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> can <z:hpo ids='HP_0003677'>slow disease progression</z:hpo> and may produce long-term remissions when given within two months of <z:hpo ids='HP_0003674'>onset</z:hpo> of clinically overt disease </plain></SENT>
<SENT sid="3" pm="."><plain>In subjects with established disease, familial clustering of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> may be related to concomitant susceptibility to <z:hpo ids='HP_0000822'>hypertension</z:hpo> and elevated rates of Na/H countertransport </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of <z:hpo ids='HP_0000822'>hypertension</z:hpo> associated with the <z:hpo ids='HP_0000112'>nephropathy</z:hpo> appears to slow renal deterioration </plain></SENT>
<SENT sid="5" pm="."><plain>Whether reversal of the metabolic consequences of insulin deficiency or resistance also prevents <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> has not been firmly established </plain></SENT>
<SENT sid="6" pm="."><plain>In the presence of a reduced Beta-cell mass, moderate <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> may itself contribute to decreased muscle <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake but not <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthesis in Type 1 and Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Reversal of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> by pancreas and islet cell transplantation, vanadate, and sulphonylureas are discussed as alternate strategies to insulin treatment in establishing normoglycaemia and furthering our understanding of insulin action and secretion at the cellular level </plain></SENT>
<SENT sid="8" pm="."><plain>There remains a need to develop more sensitive biochemical and genetic markers to identify subjects at increased risk for developing <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> </plain></SENT>
</text></document>